A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis

* Subject must be receiving peritoneal dialysis or hemodialysis for at least 3 months prior to Screening * Subject is currently being diagnosed and/or treated for secondary hyperparathyroidism * For entry into the Dosing Period (for subjects that are naïve to Vitamin D Receptor \[VDR\] Activators or those who have completed a 2 to 12 week washout), the subject must meet the following laboratory criteria prior to enrollment: * A corrected calcium value ≥ 8.2 and ≤ 10.4 mg/dL * A phosphorus value ≤ 6.5 mg/dL * An intact parathyroid hormone (iPTH) value \> 300 pg/mL and less ≤ 2000 pg/mL

* Subject is expected or scheduled to receive a living donor kidney transplant within 3 months of Screening or is a kidney transplant patient requiring full immunosuppressant therapy * Subject is expected to stop peritoneal dialysis or hemodialysis within 4 months of Screening (per investigator discretion) * Subject has had a parathyroidectomy within 12 weeks prior to Screening * Subject has had symptomatic or significant hypocalcemia requiring VDR Activator therapy (i.e., calcitriol, paricalcitol, or doxercalciferol) within 2 months prior to Screening * Subject is taking maintenance calcitonin, bisphosphonates, glucocorticoids in an equivalent dose of greater than 5 mg prednisone daily, or other drugs known to affect calcium or bone metabolism within 4 to 8 weeks prior to Dosing * Subject is receiving cinacalcet at the time of Screening